$8 million market cap, aiming for a dominant position in a predicted $10 billion market for HEP C treatments. Potential cure for HIV, influenza, Dengue, HEP B, it goes on. A successful trial completion by the end of October and results before the end of the year will see it become a classic multibagger. Now is a great time to buy in on vast amounts of capital and time spent progressing the drug to this stage where it will either be demonstrated as viable or not.
